These preclinical data suggest that CDK6 is a potential target for MLL-r leukemias; accordingly, there is an active phase Ib/IIa clinical trial out of the University of Ulm (NCT02310243) of palbociclib as monotherapy for adults with MLL-r leukemias. This evidence concerns the gene CDK6 and leukemia.